Apigenin inhibits isoproterenol-induced myocardial fibrosis and Smad pathway in mice by regulating oxidative stress and miR-122-5p/155-5p expressions

Drug Dev Res. 2022 Jun;83(4):1003-1015. doi: 10.1002/ddr.21928. Epub 2022 Mar 11.

Abstract

Apigenin, a flavonoid isolated from Apium graveolens, is an effective natural active ingredient that inhibits transforming growth factor-β1 (TGF-β1)-induced cardiac fibroblasts (CFs) differentiation and collagen synthesis. However, its effects on isoproterenol-induced myocardial fibrosis in mice remain unknown. This study aimed to examine the effect of apigenin in the prevention of myocardial fibrosis. A mouse model of myocardial fibrosis induced by isoproterenol was established, and the mice were given apigenin 75-300 mg/kg orally for 40 days. The results showed that the heart weight coefficient, myocardial hydroxyproline, collagen accumulation, and malondialdehyde levels in the apigenin-treated groups were significantly reduced. In contrast, the activity of myocardial superoxide dismutase and glutathione peroxidase were significantly enhanced. The results of real-time quantitative polymerase chain reaction and western blot assays showed that apigenin could significantly upregulate the expressions of myocardial microRNA-122-5p (miR-122-5p), c-Ski, and Smad7 and downregulate the expressions of myocardial miR-155-5p, α-smooth muscle actin, collagen I/III, NF-κB, TGF-β1, hypoxia-inducible factor-1α (HIF-1α), Smad2/3, and p-Smad2/3. In vitro, the differentiation and extracellular matrix production, as well as TGF-β1/Smads axis, were further reduced after treatment of miR-122-5p mimic or miR-155-5p inhibitor-transfected and TGF-β1-stimulated CFs with apigenin. These results suggested that apigenin increased the expression of miR-122-5p and decreased the expression of miR-155-5p, which subsequently downregulated and upregulated the target genes HIF-1α and c-Ski, respectively. Furthermore, apigenin administration downregulated TGF-β1-induced Smad2/3 and upregulated Smad7. In addition, it reduced the NF-κB/TGF-β1 signaling pathway axis by increasing antioxidant ability to exert the antifibrotic effects.

Keywords: TGF-β1/Smads; apigenin; miR-122-5p; miR-155-5p; myocardial fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apigenin* / therapeutic use
  • Cardiomyopathies* / chemically induced
  • Cardiomyopathies* / drug therapy
  • Collagen / metabolism
  • Fibrosis
  • Isoproterenol
  • Mice
  • MicroRNAs* / genetics
  • NF-kappa B / metabolism
  • Oxidative Stress*
  • Smad Proteins / metabolism
  • Transforming Growth Factor beta1 / metabolism

Substances

  • MicroRNAs
  • Mirn122 microRNA, mouse
  • Mirn155 microRNA, mouse
  • NF-kappa B
  • Smad Proteins
  • Transforming Growth Factor beta1
  • Apigenin
  • Collagen
  • Isoproterenol